Reveal is clinically validated in confirming effective therapies earlier and optimizing treatment faster in patients with advanced cancer
Guardant Health, Inc., a leading precision oncology company, announced the expansion of its Guardant Reveal® blood test to include late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal tracks more than 20,000 epigenomic (methylation) signals to measure changes in circulating tumor DNA (ctDNA) levels in a patient’s blood to predict outcomes sooner than imaging without the need for a tissue sample.
Building on Reveal’s proven performance in minimal residual disease (MRD) detection, the expanded offering leverages Guardant’s proprietary epigenomic technology powered by the Guardant Infinity Smart Platform to predict therapy response across all therapy classes, including immunotherapy and chemotherapy, which most patients with advanced-stage cancer receive at some point during their treatment. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights in just seven days.
“Guardant Reveal continues to redefine what’s possible in liquid biopsy for oncologists and patients, creating a new paradigm for therapy monitoring,” said Helmy Eltoukhy, Guardant Health Chairman and co-CEO. “By integrating therapy response monitoring into Guardant Reveal, we now have an end-to-end monitoring test built on the Infinity Smart Platform that simplifies clinical workflows and empowers providers to make faster, more informed decisions with just a simple blood draw.”
Also Read: Harbour BioMed and Evinova Form AI Partnership for Drug R&D
In addition to being the most clinically validated tissue-free test on the market, the expansion of Guardant Reveal to late-stage therapy response monitoring is supported by recent clinical evidence. The first clinical-validation study of pan-cancer chemotherapy monitoring published last week in The Journal of Liquid Biopsy showed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.
Additionally, findings from the RADIOHEAD study, a large, clinical validation study focused on immune checkpoint inhibitor response monitoring across multiple solid tumor types, showed Guardant Reveal successfully detected responses to immunotherapy up to 5 months earlier than standard imaging and identified decreases in tumor fraction were strongly associated with improved patient outcomes.
Alongside the Reveal expansion, a new universal ordering option launched today will allow physicians to order Guardant’s comprehensive portfolio of products in a single-click, providing physicians with more flexibility and reducing administrative burden to support seamless patient management from diagnosis through all stages of treatment.
Source: Businesswire